These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
88 related articles for article (PubMed ID: 9100166)
1. Treatment of branch retinal arterial occlusion with sodium ozagrel, a thromboxane A2 synthetase inhibitor. Kato H; Emura S; Takeuchi N; Enoki M; Oogushi K; Takashima T; Ohmori K; Saito I J Int Med Res; 1997; 25(2):108-11. PubMed ID: 9100166 [TBL] [Abstract][Full Text] [Related]
2. [Effects of a thromboxane-synthetase inhibitor in patients with chronic persistent coughing and no airwayhyperresponsiveness]. Nishi K; Mizuguchi M; Tachibana H; Watanabe K; Ooka T; Fujimura M; Matsuda T Nihon Kyobu Shikkan Gakkai Zasshi; 1997 Sep; 35(9):927-33. PubMed ID: 9396248 [TBL] [Abstract][Full Text] [Related]
3. Effect of ozagrel, a selective thromboxane A2-synthetase inhibitor, on cerebral infarction in rats. Comparative study with norphenazone, a free-radical scavenger. Imamura T; Kiguchi S; Kobayashi K; Ichikawa K; Yamazaki Y; Kojima M Arzneimittelforschung; 2003; 53(10):688-94. PubMed ID: 14650360 [TBL] [Abstract][Full Text] [Related]
4. Effects of sodium ozagrel on hemostatic markers and cerebral blood flow in lacunar infarction. Oishi M; Mochizuki Y; Hara M; Yoshihashi H; Takasu T Clin Neuropharmacol; 1996 Dec; 19(6):526-31. PubMed ID: 8937792 [TBL] [Abstract][Full Text] [Related]
5. [Chronic persistent coughing successfully treated with ozagrel]. Nishi K; Mizuguchi M; Tachibana H; Ooka T; Fujimura M; Matsuda T Nihon Kyobu Shikkan Gakkai Zasshi; 1996 Mar; 34(3):350-4. PubMed ID: 8778479 [TBL] [Abstract][Full Text] [Related]
6. Evaluation of a GPIIb/IIIa antagonist YM337 in a primate model of middle cerebral artery thrombosis. Kaku S; Umemura K; Mizuno A; Yano S; Suzuki K; Kawasaki T; Nakashima M Eur J Pharmacol; 1998 Mar; 345(2):185-92. PubMed ID: 9600636 [TBL] [Abstract][Full Text] [Related]
7. Thromboxane A2 synthetase inhibition suppresses cough induced by angiotensin converting enzyme inhibitors. Umemura K; Nakashima M; Saruta T Life Sci; 1997; 60(18):1583-8. PubMed ID: 9126880 [TBL] [Abstract][Full Text] [Related]
8. Effect of a selective thromboxane A2 synthetase inhibitor on the systemic changes induced by circulating pancreatic phospholipase A2. Motoyoshi M; Sugiyama M; Atomi Y; Kimura W; Nagawa H J Gastroenterol; 2006 Nov; 41(11):1094-8. PubMed ID: 17160520 [TBL] [Abstract][Full Text] [Related]
9. [Clinical effects of urokinase and sodium ozagrel in patients with acute symptomatic lacunar infarction]. Sakamoto T; Harimoto K; Inoue S; Konishi A No To Shinkei; 1996 Sep; 48(9):805-9. PubMed ID: 8888028 [TBL] [Abstract][Full Text] [Related]
14. Effect of ozagrel (OKY-046), a thromboxane synthetase inhibitor, on theophylline pharmacokinetics in asthmatic patients. Kawakatsu K; Kino T; Yasuba H; Kawaguchi H; Tsubata R; Satake N; Oshima S Int J Clin Pharmacol Ther Toxicol; 1990 Apr; 28(4):158-63. PubMed ID: 2338368 [TBL] [Abstract][Full Text] [Related]
15. The possibility of clinical application of the thromboxane A2 synthase inhibitor, ozagrel, for the treatment and prevention of preeclampsia: a preliminary report. Seki H; Kuromaki K; Takeda S; Kinoshita K; Satoh K J Obstet Gynaecol (Tokyo 1995); 1995 Aug; 21(4):357-65. PubMed ID: 8775905 [TBL] [Abstract][Full Text] [Related]
16. Trial of prophylactic administration of TXA2 synthetase inhibitor, ozagrel hydrochloride, for preeclampsia. Seki H; Kuromaki K; Takeda S; Kinoshita K; Satoh K Hypertens Pregnancy; 1999; 18(2):157-64. PubMed ID: 10476617 [TBL] [Abstract][Full Text] [Related]
17. A thromboxane A2 synthetase inhibitor as an anticoagulant for left ventricular assist devices. Takahama T; Kanai F; Onishi K ASAIO J; 1997; 43(5):M452-6. PubMed ID: 9360083 [TBL] [Abstract][Full Text] [Related]
18. Effect of ozagrel on locomotor and motor coordination after transient cerebral ischemia in experimental animal models. Ichikawa K; Tazawa S; Hamano S; Kojima M; Hiraku S Pharmacology; 1999 Nov; 59(5):257-65. PubMed ID: 10529658 [TBL] [Abstract][Full Text] [Related]
19. Ozagrel a thromboxane A2 synthase inhibitor extenuates endothelial dysfunction, oxidative stress and neuroinflammation in rat model of bilateral common carotid artery occlusion induced vascular dementia. Bhatia P; Kaur G; Singh N Vascul Pharmacol; 2021 Apr; 137():106827. PubMed ID: 33346090 [TBL] [Abstract][Full Text] [Related]
20. Thromboxane A2 synthetase inhibitor failed to ameliorate the arterial narrowing during the chronic phase of cerebral vasospasm. Toshima Y; Satoh S; Ikegaki I; Asano T; Suzuki Y; Shibuya M Life Sci; 1997; 61(14):1371-7. PubMed ID: 9335226 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]